Sunday 18 October 2026
Export HUMA’s income statement to Excel — free account
Humacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022. In the quarter to June 2026, revenue grew 34.9%, EPS grew 33.3%, free cash flow grew 17.9% and total debt rose 437.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.43
0.01
−2.27%
Follow HUMA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
86.12 | 59.86 | 74.50 | 175.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.28) | (4.81) | (5.81) | (11.52) | |
P/B ratio |
5.84 | 10.38 | 48.84 | 0.00 | |
Price to Tangible BV |
5.84 | 10.38 | 48.84 | 0.00 | |
EV/Sales |
78.94 | 67.28 | 80.36 | 180.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.72) | (1.34) | (1.56) | (2.68) | |
EV/FCF |
(1.72) | (1.32) | (1.55) | (2.66) | |
Quick Ratio |
5.37 | 3.03 | 2.77 | 0.80 | |
Current Ratio |
6.21 | 3.93 | 3.69 | 1.62 | |
Net Debt/EBITDA |
0.61 | (0.56) | (0.41) | (0.34) | |
Debt/Assets |
46.83% | 57.41% | 53.64% | 29.67% | |
Debt/Equity |
2.07 | 5.46 | 20.08 | (5.72) | |
Asset Turnover |
0.02 | 0.01 | 0.02 | 0.02 | |
Operating CF/Net income |
0.60 | 1.42 | 1.16 | 1.37 | |
Capex/Depreciation |
(0.05) | (0.08) | (0.02) | (0.03) | |
Interest Coverage |
(11.63) | (12.74) | (9.97) | (9.34) | |
Research and Development Expense of Revenue |
4,468.97% | 3,931.72% | 3,127.41% | 2,293.89% | |
Selling, General and Administrative Expense of Revenue |
1,977.09% | 1,602.02% | 1,630.84% | 1,010.62% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
642.36% | 640.40% | 528.91% | 326.83% | |
Graham Net Nets |
(0.08) | (0.29) | (0.30) | (0.20) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.39 | |
Earnings Yield |
(62.82%) | (93.44%) | (20.83%) | (13.22%) | |
Free Cash Flow Yield |
(53.41%) | (84.83%) | (69.76%) | (38.63%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.13) | (0.17) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.13) | (0.17) | (0.15) | |
Cash per Share |
0.34 | 0.25 | 0.32 | 0.12 | |
Shareholders Equity per Share |
0.13 | 0.06 | 0.02 | (0.03) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.13 | 0.06 | 0.02 | (0.03) | |
Free Cash Flow |
(22.16) | (25.28) | (26.16) | (23.95) | |
Working Capital |
77.84 | 47.41 | 49.42 | 15.77 | |
Capital Expenditures |
(0.10) | (0.17) | (0.04) | (0.05) | |
Net Current Asset Value |
(14.04) | (35.34) | (45.46) | (54.91) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | 0.35 | 0.08 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.36 | 0.46 | 0.31 | 0.55 | |
Average Payables |
5.39 | 5.33 | 4.95 | 8.24 | |
Average Inventory |
9.03 | 8.97 | — | — | |
Average Assets |
138.44 | 136.56 | 127.12 | 103.14 | |
Average Common Equity |
17.66 | 23.83 | (24.78) | (34.24) |
Columns are period end dates